Tonix Pharmaceuticals Holding Corp

NASDAQ:TNXP  
0.23
-0.02 (-7.22%)
Products

Tonix Pharmaceuticals Announces Ind Clearance For Skin Test (Tnx-2100) To Measure Sars-Cov-2 Exposure And T Cell Immunity

Published: 12/14/2021 12:23 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Announces Ind Clearance for Skin Test (tnx-2100) to Measure Sars-cov-2 Exposure and T Cell Immunity.
Tonix Pharmaceuticals Holding Corp - First-in-human Study Expected to Be Initiated in Q1 of 2022.
Tonix Pharmaceuticals - Expects to Start a Phase 1 Study on Tnx-1800 in Humans in H2 of 2022, Based on FDA Written Responses of a Pre-ind Meeting.